ABIVAX
French clinical-stage biotech developing therapies that harness the bodys natural regulatory mechanisms to stabilize the immune response in chronic inflammatory diseases.
Lead candidate obefazimod is in Phase 3 development.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 3.0% in each of the last 4 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Shareholder dilution: the share count has grown by 52.1% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 4 of the last 4 years.
Key Financial Data